PUBBLICAZIONI

1) Caraceni T, Giovannini P, Girotti F, Parati E, Pederzoli M, Scigliano G.
Long-term evaluation of combined treatment of Parkinson disease with Levodopa, peripheral decarboxylase inhibitors and bromocriptine.
Italian Journal of Neurological Science 4, 337-342, 1982 PMID: 7333824
2) Girotti F, Scigliano G, Nardocci N, Angelini L, Broggi G, Giovannini P, Caraceni T.
Idiopathic dystonia: a neuropharmacological study
Journal of Neurology 227, 239-247, 1982 PMID: 6183410
3) Girotti F, Scigliano G, Nardocci N, Angelini L, Broggi G, Giovannini P, Caraceni T.
Pharmacology of dystonia
Pharmacology 24, 126-140, 1982
4) Caraceni T, Giovannini P, Girotti F, Parati E, Scigliano G.
L’uso dei farmaci che influenzano il tono colinergico in alcune affezioni degenerative del Sistema Nervoso Centrale.
Quaderni di Acta Neurologica XLVII, 121-133, 1982
5) Giovannini P, Scigliano G, Grassi MP, Carella F, Parati E, Caraceni T.
Bromocriptine-Lisuride cross tolerance.
Ital. J. Neurol. Sci 1, 120-129, 1983 DOI 10.1007/BF02043453
6) Pederzoli M, Girotti F, Scigliano G, Aiello G, Carella F, Caraceni T.
L-Dopa long term treatment in Parkinson’s disease: age related side effects.
Neurology (Cleveland) 33, 1518-1521, November1983 PMID: 6415513
7) Caraceni TA, Parati EA, Giovannini PM, Grassi MP, Scigliano G, Carella F, Muller EE.
Neuroendocrinologic findings in patients with untreated Huntington’s chorea.
Archives of Neurology 41, 516-520, May 1984 PMID: 6232913
8) Caraceni T, Giovannini P, Parati E, Scigliano G, Grassi MP, Carella F.
Bromocriptine and Lisuride in Parkinson’s disease.
Advances in Neurology (Cleveland) 40, 531-535, 1984 PMID: 6695632
9) Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, Parati E, Caraceni T.
Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington’s disease.
Journal of Neurology Neurosurgery and Psychiatry 47, 848-852, 1984 PMID: 6147393
10) Scigliano G, Giovannini P, Girotti F, Grassi MP, Caraceni T, Schechter PJ.
Gamma-vinyl-GABA treatment in Huntington’s disease
Neurology (Cleveland) 34, 94-96, 1984 PMID: 6228746
11) Giovannini P, Grassi MP, Scigliano G, Piccolo I, Soliveri P, Caraceni T.
Deprenyl in Parkinson disease: personal experience.
Ital. J. Neurol. Sci. 6, 207-212, 1985 PMID: 3928526
12) Scigliano G, Girotti F, Caraceni T, Muller E.E.
Neuroendocrine control of pituitary function in extrapyramidal disorders.
Psychiatry 2, 273-278, 1985
13) Scigliano G, Girotti F, Caraceni T, Muller E.E.
Neuroendocrine modifications in Parkinson’s disease during DA-Agonist treatment.
In: “Dopamine and neuroendocrine active substances” Edited by E. Del Pozo and E. Flueckinger, Academic Press Inc (London) Ltd 88, 53-60, 1985
14) Carella F, Girotti F, Scigliano G, Caraceni T, Joder-Ohlenbusch AM, Schechter PJ
Double blind study of oral gamma-vinyl-GABA in the treatment of Dystonia.
Neurology (Cleveland) 36, 98-100, January 1986 PMID: 3941792
15) Girotti F, Marano R, Grazzi L, Scigliano G, Caraceni T.
Cognitive impairment in Parkinson’s disease.
Journal of Neural transmission 22, 163-170, 1986 PMID: 3465870
16) Giovannini P, Piccolo I, Scigliano G, Caraceni T.
Pharmacological approaches to Parkinson’s disease in the different phases of evolution.
Journal of Neural Transmission 22, 173-187, 1986 PMID: 3097255
17) Giovannini P, Piccolo I, Scigliano G, Grassi MP, Caraceni T
L-Deprenyl: an antiparkinsonian drug or a new strategy in the treatment of Parkinson’s disease?
New trends in Clinical Neuropharmacology, 129-136, 1987
18) Scigliano G, Giovannini P, Piccolo I, Grassi MP, Girotti F, Caraceni T
Mortality in Parkinson’s disease and Levodopa therapy.
Ital J. Neurol. Sci. 5 (7), 63, 1987
19) Girotti F, Scigliano G, Giovannini P, Piccolo I, Grassi MP, Caraceni T
Dementia in Parkinson’s disease and Alzheimer disease: clinical and neuropsychological differences.
Ital. J. Neurol. Sci. 5 (7), 28, 1987
20) Girotti F, Marano R, Soliveri P, Geminiani G, Scigliano G.
Relationship between motor and cognitive disorders in Huntington’s disease.
Journal of Neurology 235, 454-457, 1988 PMID: 2974882
21) Giovannini P, Scigliano G, Piccolo I, Soliveri P, Suchy I, Caraceni T.
Lisuride in de-novo parkinsonian patients: a four year follow-up.
Acta Neurologica Scandinavica 77, 322-327, 1988 PMID: 3291546
22) Giovannini P, Scigliano G, Piccolo I, Soliveri P, Suchy I, Caraceni T.
Lisuride in Parrkinson’s disease. 4-year follow-up.
Clinical Neuropharmacology 1988 Jun;11(3):201-11 PMID: 3401856
23) Giovannini P, Piccolo I, Genitrini S, Girotti F, Testa D, Scigliano G, Suchy I.
Terguride in the treatment of Parkinson’s disease: preliminary experience.
Ital. J. Neurol. Sci. 11, 381-385, 1990 DOI 10.1007/BF02335941; ISSN 0392-0461 (Print), 1126-5442 (Online)
24) Geminiani G, Cesana BM, Scigliano G, Soliveri P, Girotti F, Giovannini P, Caraceni T.
Variation of therapeutic response in Parkinson’s disease: a retrospective study.
Acta Neurologica Scandinavica 81, 397-401, 1990 PMID: 2375240
25) Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti F, Giovannini P, Caraceni T.
Mortality associated with early and late Levodopa therapy initiation in Parkinson’s disease
Neurology (Cleveland) 40, 265-269, 1990 PMID: 2300246
26) Giovannini P, Piccolo I, Genitrini S, Soliveri P, Girotti F, Geminiani G, Scigliano G, Caraceni T.
Early onset Parkinson’s disease.
Movement Disorders 6, 36-42, 1991 PMID: 2005920
27) Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti F, Giovannini P, Caraceni T.
Early or late L-Dopa therapy? Arguments in favour of an early beginning of L-Dopa therapy in Parkinson’s disease.
In T. Caraceni and G. Nappi Eds “Focus on Parkinson disease” (Masson) 185-194, 1991
28) Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti F, Giovannini P, Caraceni T.
Personal experience of early-onset Parkinson’s disease
In T: Caraceni and G. Nappi Eds “Focus on Parkinson’s disease” (Masson) 72-80, 1991
29) Caraceni T, Scigliano G, Musicco M
The occurrence of motor fluctuations in parkinsonian patients treated long-term with Levodopa: role of early treatment and disease progression.
Neurology (Cleveland) 41, 380-384, 1991 PMID: 2006005
30) Caraceni T, Scigliano G, Musicco M, Girotti F
A multicenter italian randomized study on early treatment of Parkinson’s disease.
In G. Nappi et al. Eds “New advances in Parkinson’s disease and others extrapyramidal disorders” Pubbl Smith Gordon 127-131, 1994
31) Palazzini E, Soliveri P, Filippini G, Fetoni V, Zappacosta B, Scigliano G, Monza D, Caraceni T, Girotti F.
Progression of motor and cognitive impairment in Parkinson’s disease.
Journal of Neurology 242, 535-540, 1995 PMID: 8530983
32) Scigliano G, Musicco M, Soliveri P, Girotti F, Giovannini P, Fetoni V, Caraceni T.
Progression and prognosis in Parkinson’s disease in relation to concomitant cerebral or peripheral vasculopathy.
Advances in Neurology. Raven Press (NY) Vol. 60, 305-309, 1996 PMID: 8615143
33) Scigliano G, Girotti F, Soliveri P, Musicco M, Radice D, Caraceni T.
Increased plasma bilirubin level in Parkinson patients on L-Dopa: evidence against the free radical hypothesis?
Ital. J. Neurol. 18, 2, 69-72, 1997 10.1007/BF01999565
34) Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F.
Reduced risk factors for vascular disorders in Parkinson’s disease patients: a case-control study.
Stroke 37:1184-1188, 2006. PMID: 16574924
35) The Italian Parkinson Study Group: Caraceni T, Musicco M, Gasparini M, Beghi E, Scigliano G, Carella F, et al. A multicenter italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, L-deprenyl and dopaminoagonists. Study design and short term results. Ital J Neurol Sci April 05, 2002 ISSN: 1126-5442
36) Scigliano G, Ronchetti G, Girotti F, Musicco M. Levodopa reduces risk factors for vascular disease in parkinsonian patients. J Neurol. 2008 Aug;255(8):1266-7. Epub 2008 May 30. PMID: 18500492
37) Scigliano G, Ronchetti G, Girotti F Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson’s disease. Neurol Sci. 2008 Feb;29(1):15-21. Epub 2008 Apr 1. PMID: 18379735
38) Scigliano G, Ronchetti G, Girotti F, Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord. 2009 Feb;15(2):138-43. Epub 2008 Jun 16. PMID: 18556236.
39) Scigliano G, Ronchetti G, Girotti F. Plasma cholesterol and Parkinson’s disease: is the puzzle only apparent? Mov Dis 2010;25:659-660
40) Scigliano G, Ronchetti G. Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis. CNS Drugs (2013) 27:249–257. DOI 10.1007/s40263-013-0054-1
41) Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention StudyActa Diabetologica
2017 | journal-article DOI: 10.1007/s00592-016-0899-0
42) N-3 fatty acids in patients with multiple cardiovascular risk factors. The New England Journal of Medicine, 01 May 2013, 368(19):1800-1808 DOI: 10.1056/nejmoa1205409
43) Scigliano Giulio and Scigliano Giuseppe Augusto. Acute respiratory distress syndrome from Covid-19: A perfect storm from free radicals? Proposal for a new treatment.Medical hypotheses
2020-07 | journal-article PMID: 32758901 DOI: 10.1016/j.mehy.2020.110120